Merck's Big Vytorin Study Could Pose A Challenge For Amgen, Sanofi, And Regeneron, Too
Sometime this month, a group of independent experts will look at the data for the key study testing Merck's blockbuster cholesterol pills, Zetia and Vytorin. They could decide that the active ingredient in both is effective – or that it is unsafe.
Sometime this month, a group of independent experts will look at the data for the key study testing Merck's blockbuster cholesterol pills, Zetia and Vytorin. They could decide that the active ingredient in both is effective – or that it is unsafe.